| Who it’s for | Class III device manufacturers, medtech startups, implant and life-sustaining device developers, and foreign manufacturers seeking U.S. approval |
| What’s covered | Pathway determination, Pre-Submissions, IDE strategy, PMA preparation, modular PMAs, FDA review and advisory panels, PMA supplements and annual reports |
| Legal basis | FD&C Act § 515; 21 CFR Part 814 |
| FDA review goal | 180 FDA days without an advisory panel, 320 FDA days with one |
| Result | An approval order allowing the device to be marketed as FDA approved for its approved indications |
What Is Premarket Approval?
FDA regulates medical devices under a three-tier, risk-based system. Class I devices face the lightest controls, Class II devices usually need 510(k) clearance, and Class III devices face the most stringent review: Premarket Approval, or PMA.
Class III devices support or sustain human life, are of substantial importance in preventing impairment of health, or present a potential unreasonable risk of illness or injury. Implantable pacemakers, heart valves and certain neurostimulators are common examples.
Unlike a 510(k), a PMA does not rely on comparison to an existing device. The sponsor must provide valid scientific evidence, usually including clinical data, that the device itself is safe and effective for its intended use. An approved PMA works like a private license to market that specific device, and it allows the device to be described as FDA approved.
Why the PMA Pathway Demands Early Planning
A PMA is often the largest regulatory investment a device company makes. Decisions made years before filing, such as study design, endpoints and manufacturing controls, decide whether FDA approves the device. Common problems we help clients avoid include:
- Clinical studies that do not support the intended claims, forcing a new or extended trial
- Refusal to file when the application is missing required elements
- Major deficiency letters that add months to review
- Failed pre-approval inspections of manufacturing and quality systems
- Negative advisory panel recommendations after weak presentation of benefit and risk
- Post-approval violations from unreported changes or missed annual reports
Developing a Class III device or unsure whether your device needs a PMA? Talk with an FDA attorney before you finalize your clinical and regulatory plan.
Schedule a ConsultationPMA Options, by Submission Type
| Submission Type | When It Fits | How It Works |
|---|---|---|
| Traditional PMA | Devices with complete data ready at filing | All sections submitted together for full FDA review |
| Modular PMA | Devices still in development or clinical study | Sections such as preclinical testing and manufacturing are submitted and reviewed in stages |
| Product Development Protocol (PDP) | Mature technologies with well-understood development paths | FDA agrees on a development and testing plan in advance |
| Humanitarian Device Exemption (HDE) | Devices for conditions affecting no more than 8,000 people in the U.S. per year | Requires safety and probable benefit rather than full effectiveness data |
| PMA Supplement | Changes to an already approved device | Review type depends on the change, such as 180-day, panel-track, real-time, or 30-day notice |
What’s Included in Our PMA Services
- Pathway determination to confirm whether your device requires a PMA or may qualify for 510(k), De Novo, or HDE
- Guidance research identifying device-specific FDA guidance documents and recognized standards
- Pre-Submission strategy to get FDA feedback on study design, endpoints and testing
- IDE support for significant risk clinical studies, including IRB and informed consent requirements
- Breakthrough Device designation requests where your device qualifies
- PMA application drafting and organization under 21 CFR 814.20
- Review management covering filing review, deficiency letters, advisory panels and pre-approval inspections
- Labeling review so indications and claims match the approval order
- Post-approval compliance including supplements, annual reports, post-approval studies and adverse event reporting
Core Service Areas
Pathway Determination and Guidance Research
Not every novel device needs a PMA. We review classification regulations, product codes and FDA precedent to confirm the correct pathway. When a PMA is required, we identify the device-specific guidance documents and recognized standards FDA will expect you to follow, so your testing plan matches FDA’s review criteria from the start.
Pre-Submissions and Breakthrough Designation
FDA’s Q-Submission program lets sponsors get written feedback on clinical protocols, statistical plans and nonclinical testing before committing to them. For devices that offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions, the Breakthrough Devices Program can provide more frequent FDA interaction and prioritized review. We prepare these requests and help you apply FDA’s feedback.
Investigational Device Exemptions (IDE)
Most PMAs rely on clinical data. A clinical study of a significant risk device generally requires an FDA-approved IDE under 21 CFR Part 812 before patients are enrolled, along with IRB oversight and informed consent. We help structure IDE submissions and sponsor obligations so the study data will hold up in the PMA.
Preparing the PMA Application
Under 21 CFR 814.20, a PMA must include the device description and indications, manufacturing methods and controls, nonclinical laboratory studies, clinical investigation results, a summary of safety and effectiveness data, proposed labeling, and other required elements. We draft and organize the application, coordinate input from engineering, clinical and quality teams, and review it against FDA’s filing checklist before submission.
FDA Review, Advisory Panels and Inspections
FDA decides within 45 days whether a PMA is complete enough to file. Substantive review follows, often with major deficiency letters that stop the clock. FDA may refer the application to an advisory panel of outside experts and will generally inspect your manufacturing facilities for compliance with its Quality Management System Regulation before approval. We manage FDA communications, prepare deficiency responses, and help you prepare for panel meetings and inspections.
PMA Supplements and Post-Approval Obligations
Approval is not the end of FDA oversight. Changes affecting safety or effectiveness generally require a PMA supplement before implementation, and many manufacturing changes require a 30-day notice. Approved devices also carry annual reporting duties, any post-approval study conditions in the approval order, and Medical Device Reporting obligations under 21 CFR Part 803. We help you classify each change and keep your approval in good standing.
Our PMA Process
- Assessment: we review your device, intended use, development stage and available data
- Strategy: we confirm the pathway and map the evidence FDA will expect
- FDA engagement: we prepare Pre-Subs, Breakthrough requests and IDE submissions as needed
- Application build: we draft and organize the PMA, traditional or modular
- Review management: we handle filing review, deficiencies, panels and inspections
- Post-approval: we support supplements, annual reports and ongoing compliance
PMA timelines vary widely based on clinical data and device complexity. We provide a realistic regulatory schedule at the start and update it as the program develops.
Why Work With an FDA Attorney on Your PMA
PMA programs involve large investments, complex data, and long-term legal exposure. An attorney adds protection that a technical consultant cannot.
- Attorney-client privilege. Internal discussions about study results, risk and regulatory strategy are generally protected.
- Product liability awareness. Courts have held that federal law can preempt certain state law claims against PMA-approved devices, which makes the accuracy and scope of your approval especially important.
- Contract support. We review agreements with clinical sites, CROs, contract manufacturers and investors that affect your regulatory position.
- Enforcement readiness. If FDA issues a Form 483, Warning Letter or questions a device change, your attorney already knows the file.
Frequently Asked Questions
- What is FDA Premarket Approval (PMA)?
- Premarket Approval is FDA’s review process for Class III medical devices. The sponsor must provide valid scientific evidence, usually including clinical data, that the device is safe and effective for its intended use. It is the most demanding device pathway FDA offers.
- Which devices require a PMA?
- Class III devices generally require a PMA. These devices support or sustain human life, are of substantial importance in preventing impairment of health, or present a potential unreasonable risk of illness or injury. Examples include implantable pacemakers, heart valves and certain implanted neurostimulators.
- What is the difference between a PMA and a 510(k)?
- A 510(k) shows a device is substantially equivalent to a legally marketed predicate and results in clearance. A PMA requires independent evidence of safety and effectiveness and results in approval. PMAs typically require clinical studies, a manufacturing inspection, and a longer review.
- How long does FDA take to review a PMA?
- FDA first decides within 45 days whether the PMA is complete enough to file. Under current user fee goals, FDA aims to decide within 180 FDA days for a PMA without an advisory panel and 320 FDA days with one. Total time is often longer once review questions and inspections are included.
- Do I need an IDE before filing a PMA?
- If your clinical study involves a significant risk device, you generally need an FDA-approved Investigational Device Exemption before enrolling patients. Studies must also have IRB approval and informed consent.
- Can a PMA device be called FDA approved?
- Yes. Devices that receive PMA approval may be described as FDA approved for their approved indications. Claims beyond those indications can make the device misbranded.
- What is a PMA supplement?
- A PMA supplement is a request for FDA approval of a change to an approved device, such as a new indication, labeling change, design change or manufacturing change. The supplement type depends on the nature of the change.
- Are there fee reductions for small businesses?
- Yes. Qualified small businesses pay reduced PMA user fees, and companies with gross receipts of $30 million or less may qualify for a waiver of the fee on their first PMA. FDA must approve the small business determination in advance. PMA. FDA must approve the small business determination in advance.
Planning a Class III device or facing a PMA deficiency letter? Our attorney will review your program and give you a clear path forward.
Toll-free: (866) 785-0873
Direct: (305) 507-9843
Email: contact@giannamore-law.com
Schedule a ConsultationThis page provides general information and is not legal advice. Reading it does not create an attorney-client relationship. FDA requirements, fees and review goals may change; contact our office for advice about your specific device.